Disprin
- Revised
- 04/10/2024
- Source updated
- 26 Nov 2024
- MA number
- PL 00063/0017.
- Legal status
- Prescription only medicine Pharmacy General Sales List
Indications
Concepts (37)
+Bleeding riskContraindicated
Hypersensitivity to acetylsalicylic acid or to any of the excipients listed in section 6.1. Hypersensitivity to other non-steroidal anti-inflammatory drugs. Nasal polyps associated with asthma. Should not be given to patients suffering from a previous history of peptic ulceration or active peptic ulceration or bleeding disorders including haemophilia. Disprin contains soy protein. If you are allergic to peanut or soya do not use this medicinal product. Severe hepatic impairment. Severe renal impairment. Severe heart failure. Children aged und
Source SmPC ↗+BreastfeedingContraindicated
Severe heart failure. Children aged under 16 years due to a possible risk of Reye's syndrome, unless specifically indicated (see section 4.4). During last trimester of pregnancy (see section 4.6). Breast-feeding (see section 4.6).
Source SmPC ↗+Heart conditionsContraindicated
leeding disorders including haemophilia. Disprin contains soy protein. If you are allergic to peanut or soya do not use this medicinal product. Severe hepatic impairment. Severe renal impairment. Severe heart failure. Children aged under 16 years due to a possible risk of Reye's syndrome, unless specifically indicated (see section 4.4). During last trimester of pregnancy (see section 4.6). Breast-feeding (see s
Source SmPC ↗+Stomach and gutContraindicated
Hypersensitivity to acetylsalicylic acid or to any of the excipients listed in section 6.1. Hypersensitivity to other non-steroidal anti-inflammatory drugs. Nasal polyps associated with asthma. Should not be given to patients suffering from a previous history of peptic ulceration or active peptic ulceration or bleeding disorders including haemophilia. Disprin contains soy protein. If you are allergic to peanut or soya do not use this medicinal product. Severe hepatic impairment. Severe renal impairment. Severe heart failure. Children aged und
Source SmPC ↗+Liver conditionsContraindicated
of peptic ulceration or active peptic ulceration or bleeding disorders including haemophilia. Disprin contains soy protein. If you are allergic to peanut or soya do not use this medicinal product. Severe hepatic impairment. Severe renal impairment. Severe heart failure. Children aged under 16 years due to a possible risk of Reye's syndrome, unless specifically indicated (see section 4.4). During last trimester of pr
Source SmPC ↗+Allergy to the medicineContraindicated
Hypersensitivity to acetylsalicylic acid or to any of the excipients listed in section 6.1. Hypersensitivity to other non-steroidal anti-inflammatory drugs. Nasal polyps associated with asthma. Should not be given to patients suffering from a previous history of peptic ulceration or acti
Source SmPC ↗+ChildrenContraindicated
ding haemophilia. Disprin contains soy protein. If you are allergic to peanut or soya do not use this medicinal product. Severe hepatic impairment. Severe renal impairment. Severe heart failure. Children aged under 16 years due to a possible risk of Reye's syndrome, unless specifically indicated (see section 4.4). During last trimester of pregnancy (see section 4.6). Breast-feeding (see section 4.6).
Source SmPC ↗+PeanutContraindicated
Nasal polyps associated with asthma. Should not be given to patients suffering from a previous history of peptic ulceration or active peptic ulceration or bleeding disorders including haemophilia. Disprin contains soy protein. If you are allergic to peanut or soya do not use this medicinal product. Severe hepatic impairment. Severe renal impairment. Severe heart failure. Children aged under 16 years due to a possible risk of Reye's syndrome, unless specifically indicated (see section 4.4).
Source SmPC ↗+PregnancyContraindicated
Severe hepatic impairment. Severe renal impairment. Severe heart failure. Children aged under 16 years due to a possible risk of Reye's syndrome, unless specifically indicated (see section 4.4). During last trimester of pregnancy (see section 4.6). Breast-feeding (see section 4.6).
Source SmPC ↗+Kidney conditionsContraindicated
ive peptic ulceration or bleeding disorders including haemophilia. Disprin contains soy protein. If you are allergic to peanut or soya do not use this medicinal product. Severe hepatic impairment. Severe renal impairment. Severe heart failure. Children aged under 16 years due to a possible risk of Reye's syndrome, unless specifically indicated (see section 4.4). During last trimester of pregnancy (see section 4.6).
Source SmPC ↗+Breathing conditionsContraindicated
Hypersensitivity to acetylsalicylic acid or to any of the excipients listed in section 6.1. Hypersensitivity to other non-steroidal anti-inflammatory drugs. Nasal polyps associated with asthma. Should not be given to patients suffering from a previous history of peptic ulceration or active peptic ulceration or bleeding disorders including haemophilia. Disprin contains soy protein. If you
Source SmPC ↗+SoyaContraindicated
Nasal polyps associated with asthma. Should not be given to patients suffering from a previous history of peptic ulceration or active peptic ulceration or bleeding disorders including haemophilia. Disprin contains soy protein. If you are allergic to peanut or soya do not use this medicinal product. Severe hepatic impairment. Severe renal impairment. Severe heart failure. Children aged under 16 years due to a possible risk of Reye's syndrome, unless specifically indicated (see section 4.4).
Source SmPC ↗+Taken with other medicinesWarning
e available. Patients with a history of GI toxicity, particularly the elderly, should report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment. Acetylsalicylic acid decreases platelet adhesiveness and increases bleeding time. Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin-reuptake inhibitors or anti-platelet agents such as clopidogrel and ticlopidine (see section 4.5). SLE and mixed connective tissue disease: Systemic lupus erythematosus and mixed connective tissue disease, due to increased risk of aseptic meningitis (see section 4.8). Dermatological effects: S
Source SmPC ↗+Older peopleWarning
l bleeding, ulceration or perforation which can be fatal, has been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a previous history of serious GI events. The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation and in the elderly. These patients should commence treatment on the lowest dose available. Patients with a history of GI toxicity, particularly the elderly, should report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment. Acetylsalicy
Source SmPC ↗+FertilityWarning
to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal. Other NSAIDs: The use with concomitant NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided. Impaired female fertility: May cause impairment of female fertility (see section 4.6). Patients with gout: The product should not be given to patients with gout, as serum urate may be increased, unless recommended by a healthcare professional. Surgical procedures: Acetylsalicylic a
Source SmPC ↗+InfectionWarning
on or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin-reuptake inhibitors or anti-platelet agents such as clopidogrel and ticlopidine (see section 4.5). SLE and mixed connective tissue disease: Systemic lupus erythematosus and mixed connective tissue disease, due to increased risk of aseptic meningitis (see section 4.8). Dermatological effects: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in ass
Source SmPC ↗+Sodium and potassium contentWarning
This medicine contains less than 1mmol sodium (23 mg) per dose, that is to state essentially 'sodium-free'. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms. Gastrointestinal effects: NSAIDs should be given with care to patie
Source SmPC ↗+BlockageWarning
stinal effects: NSAIDs should be given with care to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as their condition may be exacerbated (see section 4.8). Gastrointestinal bleeding, ulceration or perforation which can be fatal, has been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a previous history of serious GI events. The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation and in the
Source SmPC ↗+Serotonin effectsWarning
e available. Patients with a history of GI toxicity, particularly the elderly, should report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment. Acetylsalicylic acid decreases platelet adhesiveness and increases bleeding time. Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin-reuptake inhibitors or anti-platelet agents such as clopidogrel and ticlopidine (see section 4.5). SLE and mixed connective tissue disease: Systemic lupus erythematosus and mixed connective tissue disease, due to increased risk of aseptic meningitis (see section 4.8). Dermatological effects: S
Source SmPC ↗+ThyroidWarning
sed, unless recommended by a healthcare professional. Surgical procedures: Acetylsalicylic acid should be stopped several days before scheduled surgical procedures due to increased bleeding time. Laboratory tests: Acetylsalicylic acid and other salicylates can interfere with thyroid function tests. Caution should be implemented in patients with a history of other bleeding events such as intracranial haemorrhage, due to the increased risk of intercranial haemorrhage with acetylsalicylic acid us
Source SmPC ↗+UnclassifiedWarning
This medicine contains less than 1mmol sodium (23 mg) per dose, that is to state essentially 'sodium-free'. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms. Gastrointestinal effects: NSAIDs should be given with care to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as their condition may be exacerbated (see se
Source SmPC ↗+Low blood pressureInteraction
roids: Increased risk of gastrointestinal ulceration or bleeding (see section 4.4). Selective serotonin reuptake inhibitors (SSRIs): Increased risk of gastrointestinal bleeding (see section 4.4). Calcium channel blockers: Reduced hypotensive effects, increased anti-platelet effects rarely resulting in prolonged bleeding time. Cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce GFR and increase plasma cardiac glycoside levels. Varicella vaccine: Avoid use of acetylsalicylic acid in varicella vaccine recip
Source SmPC ↗+VaccinationInteraction
s, increased anti-platelet effects rarely resulting in prolonged bleeding time. Cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce GFR and increase plasma cardiac glycoside levels. Varicella vaccine: Avoid use of acetylsalicylic acid in varicella vaccine recipients due to a possible association with Reye's syndrome. Antihypertensives (ACE inhibitors and Angiotensin II Antagonists) and diuretics: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal
Source SmPC ↗+Acid build-up in the bloodInteraction
ons. Uricosurics: Acetylsalicylic acid may inhibit the effects of uricosurics. Mifepristone: NSAIDs can reduce the effect of mifepristone. Methotrexate: Decreased elimination of methotrexate. Carbonic anhydrase inhibitors e.g. Acetazolamide: May result in severe acidosis and increased central nervous system toxicity. Metamizole: Metamizole may reduce the effect of acetylsalicylic acid on platelet aggregation when taken concomitantly. Therefore, this combination should be used with caution in patients taking low
Source SmPC ↗+AlcoholNot in scanned sections
+Angioedema (deep swelling)Not in scanned sections
+Azo colourantsNot in scanned sections
+Benzyl alcoholNot in scanned sections
+DehydrationNot in scanned sections
+Salt and mineral balanceNot in scanned sections
+Enzyme deficiencyNot in scanned sections
+Intolerance to an ingredientNot in scanned sections
+Blood disordersNot in scanned sections
+LactoseNot in scanned sections
+Propylene glycolNot in scanned sections
+Blood clotsNot in scanned sections
+Gap needed after another medicineNot in scanned sections
Storage and shelf life
§6.3 — Shelf life
Three years.
§6.4 — Special precautions for storage
Store below 25°C in a dry place.